Literature DB >> 27534516

Membrane tethering of APP c-terminal fragments is a prerequisite for T668 phosphorylation preventing nuclear sphere generation.

Hassan Bukhari1, Katharina Kolbe1, Gregor Leonhardt1, Christina Loosse1, Elisabeth Schröder2, Shirley Knauer2, Katrin Marcus3, Thorsten Müller4.   

Abstract

A central molecular hallmark of Alzheimer's disease (AD) is the β- and γ-secretase-mediated cleavage of the amyloid precursor protein (APP), which causes the generation of different c-terminal fragments like C99, AICD57, or AICD50 that fully or in part contain the APP transmembrane domain. In this study, we demonstrate that membrane-tethered C99 is phosphorylated by JNK3A at residue T668 (APP695 numbering) to a higher extent than AICD57, whereas AICD50 is not capable of being phosphorylated. The modification decreases the turnover of APP, while the blockade of APP cleavage increases APP phosphorylation. Generation of nuclear spheres, complexes consisting of the translocated AICD, FE65 and other proteins, is significantly reduced as soon as APP c-terminal fragments are accessible for phosphorylation. This APP modification, which we identified as significantly reduced in high plaque-load areas of the human brain, is linearly dependent on the level of APP expression. Accordingly, we show that APP abundance is likewise capable of modulating nuclear sphere generation. Thus, the precise and complex regulation of APP phosphorylation, abundance, and cleavage impacts the generation of nuclear spheres, which are under discussion of being of relevance in neurodegeneration and dementia. Future pharmacological manipulation of nuclear sphere generation may be a promising approach for AD treatment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APP cleavage; APP intracellular domain (AICD); APP phosphorylation; Alzheimer's disease; Amyloid precursor protein (APP); Nuclear spheres

Mesh:

Substances:

Year:  2016        PMID: 27534516     DOI: 10.1016/j.cellsig.2016.08.007

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  6 in total

1.  Small Molecule Amyloid-β Protein Precursor Processing Modulators Lower Amyloid-β Peptide Levels via cKit Signaling.

Authors:  Ci-Di Chen; Ella Zeldich; Christina Khodr; Kaddy Camara; Tze Yu Tung; Emma C Lauder; Patrick Mullen; Taryn J Polanco; Yen-Yu Liu; Dean Zeldich; Weiming Xia; William E Van Nostrand; Lauren E Brown; John A Porco; Carmela R Abraham
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

2.  A delta-secretase-truncated APP fragment activates CEBPB, mediating Alzheimer's disease pathologies.

Authors:  Yinan Yao; Seong Su Kang; Yiyuan Xia; Zhi-Hao Wang; Xia Liu; Thorsten Muller; Yi E Sun; Keqiang Ye
Journal:  Brain       Date:  2021-07-28       Impact factor: 13.501

3.  A modified formulation of Huanglian-Jie-Du-Tang reduces memory impairments and β-amyloid plaques in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Siva Sundara Kumar Durairajan; Ashok Iyaswamy; Sravan Gopalakrishna Shetty; Ananth Kumar Kammella; Sandeep Malampati; Wenbin Shang; Chuanbin Yang; Juxian Song; Sookja Chung; Jiandong Huang; Kaliappan Ilango; Quan-Bin Han; Min Li
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

4.  Fe65-PTB2 Dimerization Mimics Fe65-APP Interaction.

Authors:  Lukas P Feilen; Kevin Haubrich; Paul Strecker; Sabine Probst; Simone Eggert; Gunter Stier; Irmgard Sinning; Uwe Konietzko; Stefan Kins; Bernd Simon; Klemens Wild
Journal:  Front Mol Neurosci       Date:  2017-05-11       Impact factor: 5.639

5.  Phosphorylation of the amyloid precursor protein (APP) at Ser-675 promotes APP processing involving meprin β.

Authors:  Preeti Kumaran Menon; Niina Anneli Koistinen; Kerstin Iverfeldt; Anna-Lena Ström
Journal:  J Biol Chem       Date:  2019-10-11       Impact factor: 5.157

Review 6.  Phosphorylation Signaling in APP Processing in Alzheimer's Disease.

Authors:  Tao Zhang; Dongmei Chen; Tae Ho Lee
Journal:  Int J Mol Sci       Date:  2019-12-27       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.